Comments
Shares of Dr. Reddy's Laboratories Ltd climbed as much as 4.9 per cent to Rs 2,689.65, in their biggest intraday per cent gain since November 11.
The US FDA has closed the Establishment Inspection Report (EIR) for FTO VII, the company's formulations manufacturing facility at Duvvada in south India, the drugmaker said on Saturday.
The stock closed at Rs 2,564.05, up Rs 0.70 () on the NSE, and at Rs 2,570.00, up Rs 13.10 (+0.51%) on the BSE.
EIR classifies the inspection as Voluntary Action Initiated, which Nomura says implies that the inspection observations are successfully addressed and the brokerage expects product approvals in due course.
Nomura says the development, therefore, is in line with expectations and helps address investors’ concerns.
“We think the Duvvada formulation site is important with regard to complex product filings and launches in the medium-term over the next two-three years,” said Nomura.
Nomura maintains a target price of Rs 3,478 and a “buy” rating.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.